Bupranolol

Pharmacokinetic dataBioavailability< 10%Protein binding76%MetabolismFirst pass elimination > 90%Elimination half-life2-4 hours (plasma)Excretion> 88% renal (as carboxybupranolol)IdentifiersCAS NumberPubChem CIDIUPHAR/BPSDrugBankChemSpiderUNIIKEGGChEMBLCompTox Dashboard (EPA)Chemical and physical dataFormulaC₁₄H₂₂ClNO₂Molar mass271.79 g·mol⁻¹3D model (JSmol) ^NY (what is this?)  (verify)

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and dosage

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia.^{[citation needed]} The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.^{[citation needed]}

Pharmacology

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 μg/L in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.^{[citation needed]}

Adverse effects, contraindications, interactions

Adverse effects, contraindications and interactions are similar to other beta blockers.^{[citation needed]}

References

Further reading